Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Potassium chloride provides essential potassium ion for maintaining intracellular osmotic pressure, acid-base balance, and nerve conduction. Dextrose provides calories and increases serum glucose. Sodium chloride supplies sodium and chloride ions to maintain extracellular fluid volume and electrolyte balance.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
IV infusion: 10 mEq potassium chloride in 1000 mL D5 0.45% NaCl at a rate not exceeding 10 mEq/hour; maximum 40 mEq/hour with cardiac monitoring. Adult dose typically 20-40 mEq per day, adjusted based on serum potassium.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Not applicable as potassium is an endogenous ion; serum half-life reflects redistribution and renal clearance, approximately 6-8 hours in normal renal function.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal: >90% as potassium ions, with minor fecal loss (<5%). Biliary excretion is negligible.
Category C
Category A/B
Electrolyte
Electrolyte